glp-1 cv outcome trials receptor agonists and cardiovascular trials: An update SELECT Trial

While these medications had impactful weight loss outcomes, with mean weight reduction in trials ranging from 7 to 10% [3,4,5], they lacked substantial evidence of improvement in cardiovascular outcomes

All these results highlight the underlying mechanisms of novel antidiabetic drugs in diabetic HFpEF in modulating inflammation, oxidative stress and lipotoxicity (Fig

Its important to understand that while Semaglutide GLP-1 aids in weight loss, it is primarily prescribed as a treatment for type 2 diabetes and is not a replacement for a healthy diet and regular exercise

This is what your provider tells you to take

Wegovys official safety information lists nausea, diarrhea, vomiting, constipation, stomach pain, bloating, belching, gas, and heartburn among common possible side effects, which is why this post stays practical and careful

When appetite suppression from semaglutide or tirzepatide makes eating difficult, prioritize protein above all other macronutrients